Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2008

Conditions
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Interventions
DRUG

gemcitabine

900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.

DRUG

mitoxantrone

"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."

DRUG

rituximab

"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

US Oncology Research

INDUSTRY

NCT00656084 - Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | Biotech Hunter | Biotech Hunter